SironRX Inc. spun out from Juventas Therapeutics Inc. in 2010 to develop JVS-100 for wound healing and scar prevention. The non-viral DNA plasmid encoding stromal cell-derived factor-1 is designed to tackle both indications simultaneously, while competing products are only able to address each indication distinctly.

Stromal cell-derived factor-1 is a naturally occurring chemokine that is rapidly over-expressed in response to tissue injury, particularly during ischemia. It is responsible for a variety of healing processes including the down-regulation of pro-inflammatory mediators, recruitment of endothelial progenitor and stem cells, promotion of cell preservation and stimulation of angiogenesis.